Bristol-Myers Squibb Co Price-to-Operating-Cash-Flow

: 10.81 (As of Today)

View and export this data going back to 1952. Start your Free Trial

As of today (2022-08-14), Bristol-Myers Squibb Co's share price is $75.57. Bristol-Myers Squibb Co's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2022 was $6.99. Hence, Bristol-Myers Squibb Co's Price-to-Operating-Cash-Flow Ratio for today is 10.81.

The historical rank and industry rank for Bristol-Myers Squibb Co's Price-to-Operating-Cash-Flow or its related term are showing as below:

BMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.93 Med: 12.89 Max: 97.02
Current: 10.81

During the past 13 years, Bristol-Myers Squibb Co's highest Price-to-Operating-Cash-Flow Ratio was 97.02. The lowest was 6.93. And the median was 12.89.

BMY's Price-to-Operating-Cash-Flow is ranked better than
68.68% of 680 companies
in the Drug Manufacturers industry
Industry Median: 17.53 vs BMY: 10.81

Bristol-Myers Squibb Co's Cash Flow from Operations per share for the three months ended in Jun. 2022 was $1.05. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2022 was $6.99.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Bristol-Myers Squibb Co was 26.50% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 18.70% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 29.30% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 10.90% per year.

During the past 13 years, Bristol-Myers Squibb Co's highest 3-Year average Operating Cash Flow per Share Growth Rate was 51.00% per year. The lowest was -39.20% per year. And the median was 14.45% per year.

Bristol-Myers Squibb Co Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Bristol-Myers Squibb Co's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Price-to-Operating-Cash-Flow

19.19

12.04

13.38

9.97

8.64

Bristol-Myers Squibb Co Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Price-to-Operating-Cash-Flow																12.09	8.59	8.64	10.01	11.02

Competitive Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Bristol-Myers Squibb Co Price-to-Operating-Cash-Flow Distribution

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Price-to-Operating-Cash-Flow falls into.

Bristol-Myers Squibb Co Price-to-Operating-Cash-Flow Calculation

Bristol-Myers Squibb Co's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	75.57	/	6.989
	=	10.81

Bristol-Myers Squibb Co's Share Price of today is $75.57.
Bristol-Myers Squibb Co's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.99.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Bristol-Myers Squibb Co Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

NAS:AMGN NYSE:MRK NAS:GILD NYSE:ABBV NYSE:PFE NAS:BIIB NAS:HZNP NYSE:OGN NYSE:LLY NAS:CRXT NYSE:JNJ XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN LSE:GSK XTER:BAYN TSE:4568 TSE:4519 SHSE:600276

Traded in Other Exchanges

BMY.R:USA BMYMP.PFD:USA BMY:Mexico 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Executives

Greenlees Sharon	officer: SVP & Controller	BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Shanahan Karin	officer: EVP, Glob. Prod. Dev. & Supply	BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Meyers Gregory Scott	officer: EVP, Chief Digital & Tech Off.	BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Weese Michelle	officer: EVP, Corporate Affairs	BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Hidalgo Medina Manuel	director	BRISTOL MYERS SQUIBB 430 E. 29TH STREET, 14TH FLOOR NEW YORK NY 10016
Rice Derica W	director	1000 NICOLLET MALL TPS-3155 MINNEAPOLIS MN 55403
Price Paula A	director	ONE CVS DRIVE WOONSOCKET RI 02895
Mily Elizabeth	officer: EVP, Strategy & BD	BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVENCE LINE ROAD PRINCETON NJ 08540
Metcalfe Kathryn	officer: EVP, Corporate Affairs	BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Vessey Rupert	officer: Pres., Research & Early Dev.	C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Elkins David V	officer: EVP, Chief Financial Officer	C/O BECTON, DICKINSON AND COMPANY 1 BECTON DRIVE FRANKLIN LAKES NJ 07417
Bonney Michael W	director	65 HAYDEN AVE LEXINGTON MA 02421
Yale Phyllis R	director
Ahmed Nadim	officer: President, Hematology	C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Haller Julia A	director	C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901

Bristol-Myers Squibb Co Headlines

From GuruFocus

Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma

By Business Wire 04-05-2022

Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma

By Business Wire 03-14-2022

Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl� (luspatercept-aamt) Supplemental Biologics License Application

By Business Wire 03-25-2022

Fulton Bank, N.A. Buys Bristol-Myers Squibb Co, iShares PHLX SOX Semiconductor Sector Index Fund, TotalEnergies SE, Sells Unilever PLC, PepsiCo Inc, PayPal Holdings Inc

By insider 04-05-2022

Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten

By Business Wire 04-03-2022

Key FDA Decisions Soon on Akebia, Bristol-Myers and Novartis Drugs

By 03-07-2022

Bristol Myers Squibb Announces Dividend

By Business Wire 03-01-2022

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma...

By Business Wire 02-25-2022

Bristol-Myers Squibb Co Price-to-Operating-Cash-Flow

Bristol-Myers Squibb Co Price-to-Operating-Cash-Flow Historical Data

Bristol-Myers Squibb Co Price-to-Operating-Cash-Flow Calculation

Bristol-Myers Squibb Co Price-to-Operating-Cash-Flow Related Terms

Bristol-Myers Squibb Co Business Description

Bristol-Myers Squibb Co Headlines

Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma

Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma

Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl� (luspatercept-aamt) Supplemental Biologics License Application

Fulton Bank, N.A. Buys Bristol-Myers Squibb Co, iShares PHLX SOX Semiconductor Sector Index Fund, TotalEnergies SE, Sells Unilever PLC, PepsiCo Inc, PayPal Holdings Inc

Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten

Key FDA Decisions Soon on Akebia, Bristol-Myers and Novartis Drugs

Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma...

Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers

Blockbusters From Bristol-Myers, AbbVie Losing Exclusivity

Iovance (IOVA) to Start Clinical Studies for TIL Therapy

Biotech Stock Roundup: NKTR Plunges on Study Failure, MRNA Offers Updates & More

The Zacks Analyst Blog Highlights Walmart, Adobe, Bristol-Myers Squibb Company, BHP Group and Micron Technology

Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer Study

Bristol (BMY) Label Expansion of Reblozyl Delayed by 3 Months

Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

2 Stocks Defying the Market Sell-Off Right Now

FDA Approves Bristol Myers Squibb�s Opdualag Therapy

5 Charts That Show Why Bristol-Myers Squibb Is a No-Brainer Buy

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

Prothena (PRTA) IND Application Gets FDA Clearance for AD

Amgen (AMGN) Outperforms Industry This Year So Far: What Next?

2 Warren Buffett Stocks to Buy Now and Hold Forever

Sanofi (SNY), Blackstone Ink Deal for Subcutaneous Sarclisa